Of interest, tumors with higher frequencies of SWI/SNF mutations, such as stomach adenocarcinoma (STAD), bladder (BLCA) and uterine (UCEC), showed fewer changes in NRF2 signatures than the ARID1A mutant group. The gene discussed is SMARCA1; the disease is gastric adenocarcinoma.